

Allergan plc  
Form 8-K  
July 15, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report (Date of earliest event reported): July 15, 2015**

|                    |  |                               |                           |
|--------------------|--|-------------------------------|---------------------------|
| <b>Commission</b>  | <b>Exact name of registrant as specified in its charter,</b> | <b>State of incorporation</b> | <b>I.R.S. Employer</b>    |
| <b>File Number</b> | <b>principal office and address</b>                          | <b>or organization</b>        | <b>Identification No.</b> |
| <b>001-36867</b>   | <b>Allergan plc</b>  | <b>Ireland</b>                | <b>98-1114402</b>         |
|                    | <b>1 Grand Canal Square,</b>                                 |                               |                           |
|                    | <b>Docklands Dublin 2, Ireland</b>                           |                               |                           |
|                    | <b>(862) 261-7000</b>  |                               |                           |

Edgar Filing: Allergan plc - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On July 15, 2015, Allergan plc (the Company ) issued a press release announcing that the Company received a notice letter dated July 10, 2015 from Akorn Pharmaceuticals ( Akorn ) stating that the U.S. Food and Drug Administration (FDA) has received Akorn s Abbreviated New Drug Application (ANDA) containing Paragraph IV patent certification seeking approval to market a generic version of the Company s Restasis® (cyclosporine ophthalmic emulsion) 0.05% product. In addition, the Company has received communication suggesting that additional ANDAs for generic versions of Restasis® may have been received by the FDA.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended (the Exchange Act ), or as otherwise subject to liability of that section, nor shall such information be deemed to be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

| Exhibit      | Description of Exhibit             |
|--------------|------------------------------------|
| Exhibit 99.1 | Press Release dated July 15, 2015. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 15, 2015

**ALLERGAN PLC**

By: /s/ A. Robert D. Bailey

Name: A. Robert D. Bailey

Title: Chief Legal Officer and Corporate Secretary

**Exhibit Index**

| Exhibit       | Description of Exhibit             |
|---------------|------------------------------------|
| Exhibit 99.1* | Press Release dated July 15, 2015. |

\* Exhibits filed herewith